| 42600-7 |
HIV 1+2 Ab |
PrThr |
XXX |
Pt |
Ord |
IA |
|
ACTIVE |
HIV 1+2 Ab [Presence] in Specimen by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
Non-reactive or Reactive |
|
|
|
|
|
MICRO |
|
42600-7 |
|
IA |
|
|
Both |
|
|
|
0 |
HIV1+2 Ab Spec Ql IA |
|
|
|
N |
|
ABS; Aby; AIDS; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; HIV 1 & 2; HIV 1 and 2 Ab; HIV type 1; HIV type I; HIV1; HIV1+2; Human immunodeficiency virus; i; IAA; ID; II; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; SUDS; To be specified in another part of the message; Unspecified |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42601-5 |
Immune complex.IgG |
ACnc |
Synv fld |
Pt |
Qn |
C1q binding assay |
|
ACTIVE |
Immune complex.IgG [Units/volume] in Synovial fluid by C1q binding assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
42601-5 |
|
C1q binding assay |
|
|
Both |
|
|
|
0 |
IC IgG Snv C1Q Bind-aCnc |
|
|
|
N |
|
Arbitrary concentration; Bind; CIC; Circulating immune complex; Compx; IC; IC IgG; Imm; Immune globulin G; Immunoglobulin G; Imun; Imune; Joint aspirate; Joint fld; Joint flu; Joint fluid; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; SF; SNV; Syn; Syn fl; Synov; Synovial fluid |
2.69 |
2.16 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 42602-3 |
Tropheryma whipplei DNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Tropheryma whipplei DNA [Presence] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42602-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
T whipplei DNA Bld Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; T whippelii; T whippelli; T whipplei; TMA; Transcription mediated amplification; Tropheryma whippelli; WB; Whipple's disease; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Release 2.70: COMPONENT: Corrected spelling of species name from "whippelii"; Previous Releases: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42603-1 |
Coxsackievirus A6 Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Coxsackievirus A6 Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42603-1 |
|
|
|
|
Both |
|
|
|
0 |
CV A6 Ab Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A6; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 42604-9 |
Glucose^3H post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --3 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42604-9 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 3h p Lac PO Ur-mCnc |
|
|
|
N |
|
3h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42605-6 |
Dialysis bag number |
ID |
Periton fld |
Pt |
Nom |
|
|
ACTIVE |
Peritoneal dialysis bag number |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
42605-6 |
|
|
|
|
Observation |
|
|
|
0 |
Dialysis Bag # Prt |
|
|
|
N |
|
Ascites; Ascitic fluid; Ascitis; Dialy; Dialysis Bag #; Ident; Identifier; No; Nominal; Num; Peritoneal fluid; Point in time; Prt; Random; SPEC |
2.19 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42606-4 |
Herpes simplex virus 2 Ab.IgM |
PrThr |
CSF |
Pt |
Ord |
IF |
|
ACTIVE |
Herpes simplex virus 2 IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42606-4 |
|
IF |
|
|
Both |
|
|
|
0 |
HSV2 IgM CSF Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; FA; Fluorescent antibody; Fluoresent; Herp splx; Herpes simplex virus type 2; Herpes simplex virus type II; HSV; HSV2; ID; IFA; II; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; TRF |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42607-2 |
Prolactin.monomeric |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Prolactin monomeric [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
Reference range 4 -30 |
|
|
|
|
|
CHEM |
|
42607-2 |
|
|
|
|
Both |
|
|
|
0 |
Prolactin.monomeric SerPl-mCnc |
|
|
|
N |
|
Chemistry; fPRL; Free prolactin; Lactotropic hormone; Lactotropin; Level; Mammatropic hormone; Mammotropin; Mass concentration; mPRL; Pl; Plasma; Plsm; Point in time; PRL; Prol; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.16 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 42608-0 |
Cells.CD10+CD20+/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
CD10+CD20+ cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
42608-0 |
|
|
|
|
Both |
|
|
|
0 |
CD10+CD20+ Cells NFr Mar |
|
|
|
N |
|
B1; B-1; BM; BON; Bone marrow; Bp35; CALLA; CD10 Cells; CD10+CD20+ Cells; Cell; CELL MARKERS; Cellularity; Common acute lymphoblastic leukemia; Common acute lymphoblastic leukemia antigen; Enkephalinase; gp100; J5; Leu16; Leu-16; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; NEP; Neprilysin; Neutral endopeptidase metalloendopeptidase; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 42609-8 |
Glucose^6H post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --6 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42609-8 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 6h p Lac PO Ur-mCnc |
|
|
|
N |
|
>6h; 6h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 4261-4 |
Fluoxymesterone |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Fluoxymesterone [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4261-4 |
|
|
|
|
Observation |
|
|
|
0 |
Fluoxymesterone Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; Halotestin; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 42610-6 |
Salicylurate |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Salicylurate [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
42610-6 |
|
|
|
|
Both |
|
|
|
0 |
Salicylurate SerPl-mCnc |
|
|
|
N |
|
2-hydroxybenzoylglycine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; N-(2-hydroxybenzoyl)glycine; N-(o-hydroxybenzoyl)glycine; o-hydroxyhippurate; o-hydroxyhippuric acid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; salicylglycine; salicyluric acid; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42611-4 |
Glucose^1H post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --1 hour post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42611-4 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 1h p Lac PO Ur-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p Lac PO; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42612-2 |
Salicylurate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Salicylurate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
42612-2 |
|
|
|
|
Both |
|
|
|
0 |
Salicylurate Ur-mCnc |
|
|
|
N |
|
2-hydroxybenzoylglycine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; N-(2-hydroxybenzoyl)glycine; N-(o-hydroxybenzoyl)glycine; o-hydroxyhippurate; o-hydroxyhippuric acid; Point in time; QNT; Quan; Quant; Quantitative; Random; salicylglycine; salicyluric acid; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42613-0 |
Glucose^2H post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --2 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42613-0 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 2h p Lac PO Ur-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42614-8 |
Colorado tick fever virus Ab |
Titr |
CSF |
Pt |
SemiQn |
|
|
ACTIVE |
Colorado tick fever virus Ab [Titer] in Cerebral spinal fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42614-8 |
|
|
|
|
Both |
|
|
|
0 |
CTFV Ab Titr CSF |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; CTFV; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 42615-5 |
Glucose^30M post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --30 minutes post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42615-5 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 30M p Lac PO Ur-mCnc |
|
|
|
N |
|
30M p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42616-3 |
Magnesium |
MCnc |
Dial fld |
Pt |
Qn |
|
|
ACTIVE |
Magnesium [Mass/volume] in Dialysis fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
Ref range 1.8 - 2.5 mg/dL |
|
|
|
|
|
CHEM |
|
42616-3 |
|
|
|
|
Both |
|
|
|
0 |
Magnesium Dial fld-mCnc |
|
|
|
N |
|
Chemistry; Diaf; Dialysate; Dialysis fluid; Level; MAG; Magnes; Mass concentration; Mg; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42617-1 |
Hepatitis C virus RNA |
LaCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.sig |
|
ACTIVE |
Hepatitis C virus RNA [log units/volume] (viral load) in Serum or Plasma by Probe with signal amplification |
|
MIN |
DefinitionDescription |
|
|
log IU/mL |
Reference range <2.79 |
|
|
|
|
|
MICRO |
|
42617-1 |
|
Probe.amp.sig |
|
|
Both |
|
|
|
0 |
HCV RNA SerPl Probe+sig amp-Log IU |
|
|
|
N |
|
Amplif; Amplification; Amplified; bDNA; Bdn-A; Branched Chain DNA; DNA NUCLEIC ACID PROBE; DNA probe; HC; HCV; Hep; Hep C; Hepatis; Hepatit; Hepatology; HPA; Hybidization Protection Assay; Hybrid Capture; Hybrid Capture nucleic acid hybridization; ID; Infectious Disease; InfectiousDisease; Liver; Log ACNC; Log IU; Microbiology; Pl; Plasma; Plsm; Point in time; Probe amp; Probe with ampification; Probe with signal amplification; Probe+sig amp; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Viral load |
2.73 |
2.16 |
|
|
|
|
|
|
|
{Log_IU}/mL |
|
|
|
0 |
| 42618-9 |
Naloxone |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Naloxone [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42618-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
Naloxone Ur Ql Scn |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Narcan; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42619-7 |
Cells.CD28/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
CD28 cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
42619-7 |
|
|
|
|
Both |
|
|
|
0 |
CD28 Cells NFr Mar |
|
|
|
N |
|
BM; BON; Bone marrow; CD28 Cells; Cell; CELL MARKERS; Cellularity; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; T44; Tp44 |
2.79 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 4262-2 |
Flupenthixol |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Flupenthixol [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4262-2 |
|
|
|
|
Observation |
|
|
|
0 |
Flupenthixol Dose |
|
|
|
Y |
|
Depixol; Dose med or substance; DRUG DOSES; Fluanxol; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 42620-5 |
Cells.terminal deoxyribonucleotidyl transferase/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
Terminal deoxyribonucleotidyl transferase cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
42620-5 |
|
|
|
|
Observation |
|
|
|
0 |
TdT Cells NFr Mar |
|
|
|
N |
|
BM; BON; Bone marrow; Cell; CELL MARKERS; Cellularity; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; TdT; TdT Cells |
2.79 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 42621-3 |
Mycoplasma hominis DNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycoplasma hominis DNA [Presence] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42621-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
M hominis DNA Bld Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; M hominis; Metamycoplasma hominis; Microbiology; Myco; Mycoplas; Mycoplasm; Mycoplasmosis; Mycoplsm; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; UniversalLabOrders; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42622-1 |
Cells.CD13+CD56+/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
CD13+CD56+ cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
42622-1 |
|
|
|
|
Both |
|
|
|
0 |
CD13+CD56+ Cells NFr Mar |
|
|
|
N |
|
Aminopeptidase n; APN; BM; BON; Bone marrow; CD13 Cells; CD13+CD56+ Cells; Cell; CELL MARKERS; Cellularity; gp150; Leu19; Leu-19; LeuM7; Leu-M7; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; My7; My-7; NCAM; Neural cell adhesion molecule; NKH1; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
